These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 32607238)
1. Clinical characteristics and prognostic value of the Liu SY; Sun H; Zhou JY; Jie GL; Xie Z; Shao Y; Zhang X; Ye JY; Chen CX; Zhang XC; Zhou Q; Yang JJ; Wu YL Biomark Res; 2020; 8():22. PubMed ID: 32607238 [TBL] [Abstract][Full Text] [Related]
2. The Prevalence and Concurrent Pathogenic Mutations of Liu Y; Li H; Zhu J; Zhang Y; Liu X; Li R; Zhang Q; Cheng Y Cancer Manag Res; 2021; 13():2447-2454. PubMed ID: 33758543 [TBL] [Abstract][Full Text] [Related]
3. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991 [TBL] [Abstract][Full Text] [Related]
4. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Cui W; Franchini F; Alexander M; Officer A; Wong HL; IJzerman M; Desai J; Solomon BJ Lung Cancer; 2020 Aug; 146():310-317. PubMed ID: 32619782 [TBL] [Abstract][Full Text] [Related]
5. Outcomes and prognostic contributors in patients with Burns EA; Ensor JE; Hsu J; Thomas JS; Olsen RJ; Bernicker EH J Thorac Dis; 2021 Aug; 13(8):4785-4796. PubMed ID: 34527319 [TBL] [Abstract][Full Text] [Related]
6. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Sebastian M; Eberhardt WEE; Hoffknecht P; Metzenmacher M; Wehler T; Kokowski K; Alt J; Schütte W; Büttner R; Heukamp LC; Stenzinger A; Jänicke M; Fleitz A; Zacharias S; Dille S; Hipper A; Sandberg M; Weichert W; Groschek M; von der Heyde E; Rauh J; Dechow T; Thomas M; Griesinger F; Lung Cancer; 2021 Apr; 154():51-61. PubMed ID: 33611226 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Implication of Noordhof AL; Swart EM; Damhuis RAM; Hendriks LEL; Kunst PWA; Aarts MJ; van Geffen WH JTO Clin Res Rep; 2023 Sep; 4(9):100543. PubMed ID: 37674812 [TBL] [Abstract][Full Text] [Related]
8. Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of Jing Y; Cheng R; Zeng H; Huang Q; He D; Sun J; Tian P; Li Y Int J Gen Med; 2024; 17():4507-4517. PubMed ID: 39386149 [TBL] [Abstract][Full Text] [Related]
9. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations. Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Role of Wankhede D; Bontoux C; Grover S; Hofman P Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835787 [No Abstract] [Full Text] [Related]
11. KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry. Isaksson J; Berglund A; Louie K; Willén L; Hamidian A; Edsjö A; Enlund F; Planck M; Vikström A; Johansson M; Hallqvist A; Wagenius G; Botling J Clin Lung Cancer; 2023 Sep; 24(6):507-518. PubMed ID: 37296038 [TBL] [Abstract][Full Text] [Related]
13. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent. Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080 [TBL] [Abstract][Full Text] [Related]
15. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics, outcomes and prognostic factors in KRAS mutant lung cancers: experience from a tertiary care cancer center in India. Noronha V; Sarkar L; Patil V; Menon N; Shah M; Pawar A; Chowdhury OR; Shetty O; Chougule A; Chandrani P; Kaushal R; Pai T; Janu A; Chakrabarty N; Prabhash K Ecancermedicalscience; 2024; 18():1674. PubMed ID: 38439805 [TBL] [Abstract][Full Text] [Related]
17. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110 [TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and prognostic value of the Yuan Y; Liu Y; Wu Y; Zhang J; Shen C; Zhang F; Wu C; Hu W Int J Biol Markers; 2021 Jun; 36(2):33-39. PubMed ID: 34044655 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features. Cao H; Ma Z; Li Y; Zhang Y; Chen H J Thorac Cardiovasc Surg; 2023 Dec; 166(6):e479-e499. PubMed ID: 37142051 [TBL] [Abstract][Full Text] [Related]
20. The Prognostic Effect of Wahl SGF; Dai HY; Emdal EF; Berg T; Halvorsen TO; Ottestad AL; Lund-Iversen M; Brustugun OT; Førde D; Paulsen EE; Donnem T; Andersen S; Grønberg BH; Richardsen E Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]